Cimzia's Phase III Data First In Non-Radiographic Axial Spondyloarthritis
Top-line Phase III data suggests UCB Pharma's Cimzia has benefits in a specific type of axial spondyloarthrits, with the findings expected to be submitted to the US FDA in the coming months.
